Skip to main content
OpenTrials
Completed

NCT Number: NCT01981733

Improving Lower Limb Blood Flow in Healthy Adult Volunteers

The THRIVE-1 study will examine novel methods for enhancing blood flow in the lower limb using electrical stimulation. Increases in lower limb blood flow improve venous return and thereby reduce venous stasis. Since stasis is one of the compounding factors in the development of deep vein thrombosis, the risk of developing thrombosis should theoretically be proportionally reduced. This technique may prove to be a useful tool in preventing and reducing the incidence of deep vein thrombosis in both medical and surgical patients together with passengers undertaking significant duration travel (as travel - related deep vein thrombosis is not exclusively related to flying).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Early Phase 1

Primary location

St. Bartholomew's Hospital

London, EC1A 7BE, United Kingdom

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be in good general health and fitness.
  • Aged between 18 and 65 years.
  • Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders or indications), screening physical examination, vital signs (sitting blood pressure, sitting pulse rate, sitting respiratory rate and body temperature) and duplex ultrasound within 48 hours prior to commencement of the each study phase.
  • BMI between 18 and 34
  • No history or signs of drug abuse (including alcohol), licit or illicit.
  • Has not to used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the thirty (30) days preceding the study, and agrees not to use any medications during the course of the study without informing the Research Team.
  • Able to understand the Volunteer Information Sheet and signed the written Informed Consent Forms.
  • Able and willing to follow the Protocol requirements.

Exclusion criteria

  • Any evidence of organ dysfunction, or any clinically significant deviation from normal in the physical determinations.
  • History or signs of haematological disorders (especially in relation to clotting or coagulation or previous Deep or superficial vein thrombosis/pulmonary embolism).
  • Peripheral arterial disease (ABPI < 0.9), varicose veins or lower limb ulceration.
  • Musculoskeletal disorders (such as pain during exercise of lower limb).
  • Recent surgery (such as abdominal, gynaecological, hip knee replacement).
  • Recent trauma to lower limb.
  • Chronic Obesity (BMI Index >34).
  • Pregnancy.
  • Any Medication judged to be significant by the Principal Investigator (such as anticoagulants, agents with significant vasoactive activity, Oestrogen pill, 'morning-after pill' or HRT).
  • Tobacco consumption
  • History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, endocrine, neurological, dermatological, rheumatologic, metabolic (including diabetes), psychiatric, haematological (especially in relation to clotting or coagulation), or systemic disease judged to be significant.
  • A pulse rate of less than 50 beats/minute, a sitting systolic blood pressure >160 or <80 mmHg and/or a sitting diastolic pressure of >90 or <60 mmHg.
  • Any significant illness during the four (4) weeks preceding the screening period of the study.
  • Any contraindication to blood sampling.
  • Donation of blood during the eight (8) weeks preceding the screening period of the study or during the investigation.
  • Participation in any clinical study during the 8 weeks preceding the dosing period of the study

Treatment and study plan

geko

Device

The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve

Other names: geko TM

Primary outcomes

  1. Changes in blood flow and volume, together with microcirculatory velocity were measured

    Time frame: 30 mins with 10 min washouts

    Changes in blood flow and volume, together with microcirculatory velocity were measured using laser Doppler flowmetry (Laser Doppler Perfusion & Temperature Monitor DRT4; Moor Instruments Ltd, UK) and colour flow duplex ultrasound (Philips IU22; Philips Healthcare, USA).

Sponsors and collaborators

Lead sponsor

Queen Mary University of London

Other

Registry information

Official study title

A Study to Determine the Effects of a Novel Method for Improving Lower Limb Blood Flow in Healthy Adult Volunteers

Acronym: THRIVE-1

Important dates

Study start
2005
Primary completion
2012
First posted
Nov 11, 2013
Registry last updated
Nov 11, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.